Intra-Cellular Therapies Inc (NASDAQ: ITCI)’s stock price has decreased by -5.91 compared to its previous closing price of 71.21. However, the company has seen a -7.88% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-08 that Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Is It Worth Investing in Intra-Cellular Therapies Inc (NASDAQ: ITCI) Right Now?
ITCI has 36-month beta value of 1.00. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITCI is 102.73M, and currently, short sellers hold a 3.50% ratio of that float. The average trading volume of ITCI on May 09, 2024 was 977.65K shares.
ITCI’s Market Performance
ITCI’s stock has seen a -7.88% decrease for the week, with a -2.36% drop in the past month and a -2.29% fall in the past quarter. The volatility ratio for the week is 4.89%, and the volatility levels for the past 30 days are at 4.51% for Intra-Cellular Therapies Inc The simple moving average for the past 20 days is -6.43% for ITCI’s stock, with a 7.07% simple moving average for the past 200 days.
Analysts’ Opinion of ITCI
Many brokerage firms have already submitted their reports for ITCI stocks, with Robert W. Baird repeating the rating for ITCI by listing it as a “Outperform.” The predicted price for ITCI in the upcoming period, according to Robert W. Baird is $83 based on the research report published on January 03, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $75. The rating they have provided for ITCI stocks is “Outperform” according to the report published on December 11th, 2023.
Morgan Stanley gave a rating of “Overweight” to ITCI, setting the target price at $80 in the report published on April 20th of the previous year.
ITCI Trading at -3.16% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.07% of loss for the given period.
Volatility was left at 4.51%, however, over the last 30 days, the volatility rate increased by 4.89%, as shares sank -0.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.09% lower at present.
During the last 5 trading sessions, ITCI fell by -7.88%, which changed the moving average for the period of 200-days by +8.89% in comparison to the 20-day moving average, which settled at $71.59. In addition, Intra-Cellular Therapies Inc saw -6.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITCI starting from Mates Sharon, who sale 20,565 shares at the price of $65.21 back on Mar 11 ’24. After this action, Mates Sharon now owns 1,050,309 shares of Intra-Cellular Therapies Inc, valued at $1,341,123 using the latest closing price.
Hineline Lawrence J., the SVP of Finance, CFO of Intra-Cellular Therapies Inc, sale 10,121 shares at $65.96 during a trade that took place back on Mar 11 ’24, which means that Hineline Lawrence J. is holding 0 shares at $667,587 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.93 for the gross margin
The net margin for Intra-Cellular Therapies Inc stands at -0.3. The total capital return value is set at -0.26. Equity return is now at value -18.07, with -15.09 for asset returns.
Based on Intra-Cellular Therapies Inc (ITCI), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.33. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 36.65.
Currently, EBITDA for the company is -158.85 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of 13.75. The receivables turnover for the company is 4.05for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.12.
Conclusion
To put it simply, Intra-Cellular Therapies Inc (ITCI) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
